KREBSBIOPharmaceuticals
Krebs Biochemicals & Industries Limited — Profit & Loss Statement
₹39.75
-6.96%
Krebs Biochemicals & Industries Limited Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Expenses | 65.03 Cr | 65.91 Cr | 74.07 Cr | 99.20 Cr | — |
| Diluted Average Shares | 2.16 Cr | 2.16 Cr | 2.16 Cr | 2.16 Cr | — |
| Basic Average Shares | 2.16 Cr | 2.16 Cr | 2.16 Cr | 2.16 Cr | — |
| Diluted EPS | -12.49 | -9.15 | -11.30 | -20.81 | — |
| Basic EPS | -12.49 | -9.15 | -11.30 | -20.81 | — |
| Diluted NI Availto Com Stockholders | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Net Income Common Stockholders | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Net Income Including Noncontrolling Interests | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Net Income Continuous Operations | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Tax Provision | 0.02 Cr | 0.00 | 0.00 | 0.00 | — |
| Pretax Income | -26.92 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Other Non Operating Income Expenses | 0.71 Cr | 0.45 Cr | 0.62 Cr | 1.02 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | -5.91 Cr | -4.69 Cr | -2.75 Cr | -5.03 Cr | — |
| Interest Expense Non Operating | 5.91 Cr | 4.69 Cr | 2.97 Cr | 5.38 Cr | — |
| Operating Income | -21.72 Cr | -15.49 Cr | -21.94 Cr | -39.49 Cr | — |
| Operating Expense | 59.48 Cr | 59.32 Cr | 31.72 Cr | 33.73 Cr | — |
| Other Operating Expenses | 36.19 Cr | 36.08 Cr | 4.88 Cr | 7.47 Cr | — |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.30 | 0.00 | 0.00 | 0.00 | — |
| Normalized EBITDA | -14.32 Cr | -8.27 Cr | -15.16 Cr | -32.85 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Reconciled Depreciation | 6.69 Cr | 6.77 Cr | 6.56 Cr | 6.30 Cr | — |
| Reconciled Cost Of Revenue | 5.56 Cr | 6.59 Cr | 42.35 Cr | 65.47 Cr | — |
| EBITDA | -14.32 Cr | -8.27 Cr | -15.16 Cr | -32.85 Cr | — |
| EBIT | -21.01 Cr | -15.04 Cr | -21.72 Cr | -39.14 Cr | — |
| Net Interest Income | -5.91 Cr | -4.69 Cr | -2.75 Cr | -5.03 Cr | — |
| Interest Expense | 5.91 Cr | 4.69 Cr | 2.97 Cr | 5.38 Cr | — |
| Normalized Income | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Net Income From Continuing And Discontinued Operation | -26.94 Cr | -19.73 Cr | -24.69 Cr | -44.53 Cr | — |
| Depreciation And Amortization In Income Statement | 6.69 Cr | 6.77 Cr | 6.56 Cr | 6.30 Cr | — |
| Depreciation Income Statement | 6.69 Cr | 6.77 Cr | 6.37 Cr | 5.66 Cr | — |
| Gross Profit | 37.76 Cr | 43.83 Cr | 9.78 Cr | -5.76 Cr | — |
| Cost Of Revenue | 5.56 Cr | 6.59 Cr | 42.35 Cr | 65.47 Cr | — |
| Total Revenue | 43.31 Cr | 50.42 Cr | 52.13 Cr | 59.70 Cr | — |
| Operating Revenue | 43.31 Cr | 50.42 Cr | 52.13 Cr | 59.70 Cr | — |
| Rent Expense Supplemental | — | 0.58 Cr | 0.69 Cr | 0.68 Cr | 0.94 Cr |
| Total Other Finance Cost | — | 35000.00 | 22000.00 | 64000.00 | 73000.00 |
| Interest Income Non Operating | — | 0.16 Cr | 0.22 Cr | 0.36 Cr | 0.07 Cr |
| Interest Income | — | 0.16 Cr | 0.22 Cr | 0.36 Cr | 0.07 Cr |
| Amortization | — | 0.18 Cr | 0.18 Cr | 0.64 Cr | 0.26 Cr |
| Selling General And Administration | — | 0.60 Cr | 0.86 Cr | 1.14 Cr | 0.68 Cr |
| General And Administrative Expense | — | 0.60 Cr | 0.86 Cr | 1.14 Cr | 0.67 Cr |
| Rent And Landing Fees | — | 0.58 Cr | 0.69 Cr | 0.68 Cr | 0.31 Cr |
| Net Income Discontinuous Operations | — | — | — | 0.00 | 0.00 |
| Other Special Charges | — | — | — | 0.18 Cr | 0.05 Cr |
| Write Off | — | — | — | 0.00 | 0.08 Cr |
| Selling And Marketing Expense | — | — | — | 38000.00 | 47000.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Krebs Biochemicals & Industries Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.